CAPZB

Across TCGA pan-cancer cohorts, CAPZB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CAPZB data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CAPZB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAPZB expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

COAD, GBM, and CCRCC are the cancer types where CAPZB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.868	1.000	.010	72	view →
GBM	DFS	Quartile	All	0.469	0.804	<.001	18	view →
CCRCC	OS	Quartile	All	0.683	0.964	.003	13	view →
LSCC	DFS	Tertile	II,III,IV	0.522	0.856	.017	6	view →
LUAD	DFS	Tertile	II,III,IV	0.687	0.331	.016	2	view →
PDAC	DFS	Tertile	III,IV	0.798	0.466	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CAPZB–COAD (DFS)

Open the COAD breakdown →